Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-10-23
2007-10-23
Landsman, Robert S. (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S085200, C435S039000, C435S069700, C530S351000
Reexamination Certificate
active
09980916
ABSTRACT:
Improvements in therapy and prevention of conditions characterized by an elevated level of eosinophil leukocytes, i.e. conditions such as asthma and other chronic allergic diseases are disclosed. A method is provided for down-regulating interleukin 5 (IL5) by enabling the production of antibodies against IL5 thereby reducing the level of activity of eosinophils.
REFERENCES:
patent: 5096704 (1992-03-01), Coffman et al.
patent: 5616488 (1997-04-01), Sullivan et al.
patent: 6093405 (2000-07-01), Zagury et al.
patent: 2004/0141958 (2004-07-01), Steinaa et al.
patent: WO93/23076 (1993-11-01), None
patent: WO95/05849 (1995-03-01), None
patent: WO95/05849 (1995-03-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO95/07707 (1995-03-01), None
patent: WO95/26365 (1995-10-01), None
patent: WO95/26365 (1995-10-01), None
patent: WO95/31480 (1995-11-01), None
patent: WO95/31480 (1995-11-01), None
patent: WO95/35375 (1995-12-01), None
patent: WO97/00321 (1997-01-01), None
patent: WO97/00321 (1997-03-01), None
patent: WO 97/00321 (1997-03-01), None
patent: WO97/45448 (1997-12-01), None
patent: WO97/45448 (1997-12-01), None
patent: WO98/17799 (1998-04-01), None
patent: WO98/17799 (1998-04-01), None
patent: WO98/23635 (1998-06-01), None
patent: WO 98/23635 (1998-06-01), None
patent: WO 98/31398 (1998-07-01), None
patent: WO98/31398 (1998-07-01), None
patent: WO98/47923 (1998-10-01), None
patent: WO98/47923 (1998-10-01), None
Mann et. al., Medical Hypotheses, In Press, Corrected Proof, Available online Oct. 14, 2004.
Riley et al., Pharmacogenomics 2000, vol. 1(1): pp. 39-47.
Luck et al., Molecular Endocrinology 1991, vol. 5(12): pp. 1880-1886, esp. p. 1881, table 1.
Dalum et al., Mol Immunol. 1997, vol. 34(16-17): pp. 1113-1120.
Elenkov et al., Ann N Y Acad Sci. 2002, vol. 966: pp. 290-303, esp. p. 291: paragraph 2.
Sher. A., et al. 1990. Proc. Natl. Acad. Sci. USA. vol. 87, pp. 61-65.
Mori, A., et al. 1997. J. Allergy Clin. Immunol. vol. 100(6 Pt. 2), pp. S56-S64.
Lee, N.A., et al. 1997. J. Immunol. vol. 158, pp. 1332-1344.
Lee N.A. et al. Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and uniquie histopathologies. 1997. J. Immunol. vol. 158, p. 1332-1344.
K. Takatsu, “Interleukin 5 and B cell differentiation,” Cytokine and Growth Factor Reviews, vol. 9, No. 1, pp. 25-35 (Mar. 1998).
J. Weltman et al., “Interleukin-5: a proeosinophil cytokine mediator of imflammation in asthma and a target for antisense therapy”, Allergy and Asthma Proceedings, vol. 19, No. 5, pp. 257-261 (Sep. 1998).
D. Broide et al., “Intradermal gene vaccination down-regulates both arms of the allergic response”, Journal of Allergy and Clinical Immunology, vol. 99, No. 1, part 2, p. S129 (Jan. 1997).
The Journal of Immunology 160((1998) 3363-73 Southwood et al “Several common.”
Scand J Immunol 47(1998) 596-602 Ohashi et al “Allergen-induced synthesis . . . ”.
J Exp Med 185(12) (Jun. 16, 1997) 2143-56 Lee et al “Interleukin-5 . . . ”.
The Journal of Immunology 158(1997) 1332-44 Lee et al “Expression of IL-5 . . . ”.
Am J Respir Crit Care Med 154 (1996) 850-7 Underwood et al “Persistent . . . ”.
J Exp Med 183 (Jan. 1996) 195-201 Foster et al “Interleukin 5 deficiency.”
Am J Respir Cell Mol Biol 13(1995) 360-65 Kung et al “Involvement of IL-5 . . . ”.
Am J Respir Crit Care Med 151(1995) 177-83 van Oosterhout et al “Antibody . . . ”.
The Journal of Immunology 155(1995) 3946-54 Villinger et al “Comparative . . . ”.
Am J Respir Crit Care Med 150(1994) S50-S53 Cousins et al “Regulation . . . ”.
Am Rev Respir Dis 147(1993) 548-552 van Oosterhout et al “Effect of Anti-IL . . . ”.
Am Rev Respir Dis 148(1993) 1623-27 Mauser et al “Inhibitory effect of the . . . ”.
J Exp Med 178(Jul. 1993) 27-47 Chiez et al “Specificity and promiscuity . . . ”.
Life Sciences 53(1993) PL 243-47 Nagai et al “Effect of anti-IL-5 . . . ”.
Immunology Today 13(12 (1992) 495-500 Lopez et al “GM-CSF, IL-3 and IL-5 . . . ”.
Blood 78(10) (Nov. 15, 1991) 2542-47 Yamaguchi et al “Analysis of the . . . ”.
The Journal of Immunology 144(4) (Feb. 15, 1990) 1345-52 Tominaga et al.
DNA 8(7) (1989) Tavernier et al “Expression of human and murine . . . ”.
Nature 336(Dec. 22-29, 1988) 778-80 Sinigaglia et al “A malaria t-cell . . . ”.
The Journal of Biological Chemistry 262(34) (Dec. 5, 1987) 16580-4 Tanabe.
Nucleic Acids Research 14(22) (1986) Azuma et al “Cloning of cDNA for . . . ”.
Cytokine and Growth Factor Reviews, 9(1) 25-35 (1998) Takatsu “Interleukin . . . ”.
Allergy and Asthma Proc. (Sep./Oct. 1998) 19(5) 257-61 Weltman et al.
J. of Allergy and Clinical Immunology, 99(1), Part 2 Broide et al.
Hertz et al. “Active Vaccination Against IL-5 Bypasses Immunological Tolerance and Ameliorates Experimental Asthma” The Journal of Immunology, 2001, 167: 3792-3799.
Nature Biotechnology 17(Jul. 1999) 666-9 Dalum et al “Therapeutic antibodies.”
Intern Rev Immunol 16(1998) 227-47 Karlen et al “Biological and molecular . . . ”.
J Allergy Clin Immunol 101(1998) 222-30 Barata et al “IL-4-and IL-5-positive.”
The Journal of Immunology 160(1998) 4427-32 Wang et al “Selective inhibition .”
Allergy, Ed: Kaplan, AP (1997) Orgega et al Chapter 28, “Asthma”.
Allergy 52(1997) 787-94 Danzig et al “Inhibition of interleukin-5 . . . ”.
PubMed Abstract 9117011, Am J Respir Crit Care Med 155(3) (Mar. 1997) 819-25.
J Allergy Clin Immunol 100(1997) S56-64 Mori et al “Cellular and molecular . . . ”.
J Exp Med 185(12) (Jun. 16, 1997) 2143-56 Lee et al “Interleukin-5 . . . ”.
Methods: A companion ot Methods in Enzymology 11(1997) 88-97 Baumann et al.
Eur Respir J 9(Suppl 22) (1996) 72s-78s Corrigan et al “T-cell/eosinophil . . . ”.
Immunity 4(Jan. 1996) 15-24 Kopf et al “IL-5 Deficient mice have . . . ”.
Journal of Immunology 156(1996) 1392-1401 Huston et al “Human B cells . . . ”.
Am J Respir Crit Care Med 154 (1996)850-7 Underwood et al “Persistent . . . ”.
J Exp Med 183(Jan. 1996) 195-201 Foster et al “Interleukin 5 deficiency .”
The Journal of Immunology 157 (1996) 4796-4804 Dalum et al “Breaking of B . . . ”.
J Mol Med 74(1996) 535-546 Dickason et al “Engineering of a functional . . . ”.
Journal of Protein Chemistry 15(5) (1996) 491-99 Proudfoot et al “The carboxy .”
Nature 379 (Feb. 15, 1996) 652-55 Dickason et al “Creation of a . . . ”.
Am J Respir Crit Care Med 152(1995) 467-72 Mauser et al “Effects of an . . . ”.
Immunology Letters 45(1995) 109-116 Akutsu et al “Antibody against . . . ”.
Int Arch Allergy Immunol 107(1995) 321-22 Egan et al “Inhibition of . . . ”.
The Journal of Biological Chemistry 270(26) (Jun. 30, 1995) 15762-15769 Graber.
B J Pharmacol 113(1994) 749-56 Coeffier et al “Role of interleukin-5 . . . ”.
Cytokine 6(6) (Nov. 1994) 647-56 Dickason et al “Enhanced detection . . . ”.
Immunogenetics 39 (1994) 230-242 Falk et al “Pool sequencing of natural . . . ”.
Thorax 49 (1994) 1231-33 Alexander et al “Serum interleukin 5 . . . ”.
Am Rev Respir Dis 148 (1993) 1623-27 Mauser et al “Inhibitory effect of the . . . ”.
Annals of NY Acad Sci (1993) 91-6 Nagai et al “The role of interleukin-5 . . . ”.
Cell 74 (Jul. 16, 1993) 197-203 Hammer et al “Promiscuous and allele . . . ”.
Eur J Biochem 212 (1993) 751-55 Graber et al “Purification, . . . ”.
Eur J Biochem 211 (1993) 903-08 Kodama et al “Role of sugar chains in . . . ”.
J Exp Med 178(Jul. 1993) 27-47 Chicz et al &#x
Hissong Bruce D.
Landsman Robert S.
Pharmexa A/S
LandOfFree
Method for down-regulating IL5 activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for down-regulating IL5 activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for down-regulating IL5 activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3899152